PositoAI/ US/ Krystal Biotech, Inc.

Krystal Biotech, Inc.

NasdaqGS: KRYS · Healthcare

Positivity Index

#4,945 / 6,774

Global

#2,602 / 4,000

United States

Positivity Score

18,710

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Krystal Biotech, Inc. — Overview & Financial Snapshot

Krystal Biotech, Inc. (NasdaqGS: KRYS) is a Healthcare company, ranked #4,945 of 6,774 companies globally and #2,602 of 4,000 in United States on PositoAI, with a Positivity Score of 18,710. Its market capitalisation is ₹89,439.79 Cr ($9.48B), P/E ratio is 40.1 and P/B ratio is 6.97. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

P/B Ratio 6.97

P/E Ratio 40.1

D/E Ratio 0.01

ROE 20.12%

Owes vs Owns ? 0.09× Low $0.09 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹753.24$7.98

Forward EPS ₹845.01$8.95

Beta 0.50

Market Cap ₹89,439.79 Cr$9.48B

What these numbers mean →

What does Krystal Biotech, Inc. do?

What is Krystal Biotech, Inc.'s P/E and P/B ratio?

Krystal Biotech, Inc. has a P/E ratio of 40.1 and a P/B ratio of 6.97.

What is Krystal Biotech, Inc.'s debt-to-equity ratio?

Krystal Biotech, Inc. has a debt-to-equity ratio of 0.01.

How much does Krystal Biotech, Inc. owe compared with what it owns?

Krystal Biotech, Inc. owes $0.09 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Krystal Biotech, Inc.'s Positivity rank?

Krystal Biotech, Inc. is ranked #4,945 of 6,774 companies globally and #2,602 of 4,000 in United States on PositoAI, with a Positivity Score of 18,710.

Does Krystal Biotech, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Krystal Biotech, Inc..

Where can I read the latest news about Krystal Biotech, Inc.?

Recent headlines about Krystal Biotech, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Krystal Biotech, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Krystal Biotech, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.